We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+21.02%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$53.9M
(-18%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-28.78%
Top 10 Holdings %
Top 10 Hldgs %
66.57%
Holding
44
New
15
Increased
7
Reduced
6
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$24.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$15M |
| 3 |
Merck
MRK
|
+$13.8M |
| 4 |
SkinHealth Systems
SKIN
|
+$11.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$38.3M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$15.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$15.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$14.1M |
| 5 |
Cigna
CI
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.2% |
| 2 | Consumer Staples | 5.21% |
| 3 | Financials | 2.89% |
| 4 | Industrials | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Femasys
FEMY
$9.21M
| $1.31M | 0.52% |
9,530
+92
| +1% | +$13.5K |
|
27
Theravance Biopharma
TBPH
$875M
| $956K | 0.38% |
+129,192
| New | +$1.45M |
|
|
CCXI
28
DELISTED
ChemoCentryx, Inc.
CCXI
| $274K | 0.11% |
+16,045
| New | +$250K |
|
29
Aldeyra Therapeutics
ALDX
$92.9M
| – | – |
-818,025
| Closed | -$9.27M |
|
30
argenx
ARGX
$52.9B
| – | – |
-6,408
| Closed | -$1.93M |
|
|
31
Cigna
CI
$72.3B
| – | – |
-50,699
| Closed | -$12M |
|
32
Celldex Therapeutics
CLDX
$3.06B
| – | – |
-175,305
| Closed | -$5.86M |
|
33
Evolus
EOLS
$398M
| – | – |
-496,826
| Closed | -$6.29M |
|
34
CALL
Fulgent Genetics
FLGT
$529M
| – | – |
-50,000
| Closed | -$4.61M |
|
35
Humana
HUM
$43.6B
| – | – |
-11,305
| Closed | -$5M |
|
|
36
Jazz Pharmaceuticals
JAZZ
$16.4B
| – | – |
-89,370
| Closed | -$15.9M |
|
|
37
Johnson & Johnson
JNJ
$611B
| – | – |
-85,596
| Closed | -$14.1M |
|
|
MREO
38
Mereo BioPharma
MREO
$51.6M
| – | – |
-1,253,729
| Closed | -$3.97M |
|
39
Moderna
MRNA
$22.8B
| – | – |
-19,193
| Closed | -$4.51M |
|
40
Pfizer
PFE
$145B
| – | – |
-202,692
| Closed | -$7.94M |
|
|
41
Protagonist Therapeutics
PTGX
$8.81B
| – | – |
-341,650
| Closed | -$15.3M |
|
42
CALL
Teva Pharmaceuticals
TEVA
$40B
| – | – |
-445,900
| Closed | -$4.41M |
|
|
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-150,783
| Closed | -$6.16M |
|
|
ENDP
44
CALL
DELISTED
Endo International plc
ENDP
| – | – |
-1,048,100
| Closed | -$4.91M |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q3 2021 Portfolio in Review
As of Q3 2021, Tri Locum Partners held 44 positions worth $252M, down 18% from $306M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Tri Locum Partners withdrew a net $72.4M in Q3 2021, closing 16 positions and reducing 6 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $15.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Tri Locum Partners opened a new position in Baxter International worth $25.1M.
- Tri Locum Partners's largest Q3 2021 buy was Baxter International: 312,400 shares worth $25.1M.
- Tri Locum Partners added most to Edwards Lifesciences in Q3 2021, an estimated $8.52M increase.
- Tri Locum Partners's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $38.3M.
- Tri Locum Partners fully exited Jazz Pharmaceuticals in Q3 2021, selling an estimated $15.9M.
- Tri Locum Partners's ten largest holdings make up 67% of its $252M portfolio in Q3 2021.
- Tri Locum Partners opened 15 new positions and closed 16 in Q3 2021.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $252M.
Based on Tri Locum Partners's 13F filing for Q3 2021, filed 15 Nov 2021.